Immunotherapy and targeted drug treatment for kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a combination of immunotherapy and targeted drugs (called IO/TKI) given before and after surgery for clear cell renal cell carcinoma (a type of kidney cancer). The goal is to shrink tumors and improve survival outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with clear cell renal cell carcinoma (a specific type of kidney cancer) confirmed by biopsy
- Ages 18–80 and able to give informed consent
- Good overall health status (ECOG 0 or 1, meaning you can do light activities)
- Never received chemotherapy, immunotherapy, or other cancer drugs before
- Blood tests show adequate kidney, liver, and heart function, and healthy blood cell counts
- No brain metastases (cancer spread to the brain) or active infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs — an immunotherapy (toripalimab) and a targeted therapy (axitinib) — as the first treatment for advanced kidney cancer. The approach may shrink the tumor before deciding whether and when to remove the kidney surgically.
This trial tests if a combination of targeted embolization, immunotherapy (Toripalimab), and a targeted therapy pill (Axitinib) can shrink advanced kidney cancer before surgery. It is for patients whose cancer has spread to nearby tissues or lymph nodes, or has limited spread elsewhere that can be removed.
This trial tests a combination of two drugs—an immunotherapy called toripalimab and a targeted therapy called axitinib—for people with rare kidney cancers that have spread. The goal is to see if this combination can shrink or control the cancer before any surgery to remove the kidney.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether the drug toripalimab can prevent kidney cancer from coming back in people who have had their kidney and any visible metastases surgically removed. It focuses on patients with high-risk features or who had some metastatic spots taken out completely.
This trial tests a new drug (JS004) combined with an existing immunotherapy (toripalimab) for kidney cancer that has progressed after previous immunotherapy. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
Hear when a new Clear Cell RCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.